Current hematology/oncology fellow @MDAndersonNews | Former resident @UTSWInternalMed | Alum @BUMedicine
Houston, TX
Joined January 2023
- Tweets36
- Following201
- Followers123
- Likes701
Mir Lim retweeted
Thrilled to congratulate everyone on Match Day, especially the newly matched @MDAndersonNews Hematology & Medical Oncology Fellowship Class of 2029! #EndCancer
Mir Lim retweeted
What an incredible week at the ASCO/AACR Methods in Clinical Cancer Research Workshop! Grateful and inspired by all of the amazing fellows and mentors @ASCO @AACR #vailworkshop #PDG6 #colorectalcancer #CRC @sepideh_gholami @manjuggm @YoussefBouferra @MirLimMD @Guv_onc
Mir Lim retweeted
Congratulations to the @MDAndersonNews trainees who received 2025 @ConquerCancerFd Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!
Mir Lim retweeted
Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues
@OncoAlert @AnnPartridgeMD @oncofertility
Link:
ascopubs.org/doi/10.1200/JCO…
Mir Lim retweeted
Grateful for the opportunity to work with the incredible @VanMorrisMD on this phase I/II trial of encorafenib, cetuximab and nivolumab in pts with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF + EGFR targeted tx.
- While the addition of Nivo did not seem to overcome resistance after progression on prior E+C, there remains a role of E+C+N in the BRAF tx naive population
Mir Lim retweeted
6. #BREAKWATER: Ph 3, Enco + Cetux + mFOLFOX vs SoC in BRAFV600E mCRC
- ORR 61% vs 40%
- Interim OS at 12mos 79.5% vs 66%
- Gr≥3 AEs: 37.7% vs 34.6%
- New SoC for BRAFV600E
7/8
Results of Phase III BREAKWATER for BRAF V600E MT stage IV tx naive pts fulfilled primary endpoint for ORR (61% vs. 40%) and early trend for OS (add'l data to follow) defining a NEW standard of care. #colorectal #cancer @ASCO #ASCOGI25 #colorectal #CancerResearch @NatureMedicine #crcsm @PfizerOncMed @FDAOncology
Mir Lim retweeted
#GI25 highlights #CommunityOnc:
1. #SCIENCE: Adv Eso SCC
2. #ESOPEC publication (Eso/GEJ/Ga)
3. Chemo in resectable Panc Ca
4. #StarterNET: GEP-NET
5. #CM8HW: dMMR/MSI-H mCRC
6. #BREAKWATER: BRAFV600E mCRC
7. ctDNA: #BESPOKE + SWOG80702
#OncTwitter #gism @ASCO
1/8
Mir Lim retweeted
Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic?
Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer.
(Significant AEs: rash, diarrhea, nausea, vomiting)
dailynews.ascopubs.org/do/pa…
Mir Lim retweeted
#GI25
BREAKWATER
@skopetz changing the paradigm yet again! The true master of BRAF and colorectal targeted therapy.
BRAF+ first line mCRC; n=236 on experimental arm
Enco (BRAF) + Cetux (EGFR)+ FOLFOX
ORR 60% vs 40%!
OS not yet reached!!!
Durable responses and twice as high in experimental arm.
Well tolerated, amazing design to tease out contribution of components.
New standard of care in BRAF+ disease.
@OncoAlert
Mir Lim retweeted
Great data for pts w/ 2+ line met anal cancer for pembrolizumab+ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets+pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! @MDAndersonNews #endcancer @BicaraTx
Mir Lim retweeted
#GI25 @ASCO #LBA🌟
🚨CM8HW in dMMR #mCRC - the awaited nivo/ipi1 vs nivo PFS 🙌
📌 N=707 across all
lines, 55% 1L, centrally confirmed
📌 PFS HR 0.62, p0.0003 👉3 yr PFS 68% v 51%
📌 ORR 71% vs 58% - PD 10% w/ combo
📌 safely reassuring🤙
➡️nivo/ipi is the new SOC for dMMR mCRC
➡️reserve pembro if ineligle for +CTLA4
…already in NCCN 🇺🇸 ESMO 🇪🇺… 🤞🇨🇦soon!
@OncoAlert @coloncanada @ccranorg
Mir Lim retweeted
SOOOO proud of our @MDAndersonNews med onc star fellows @MichaelLaPelusa, @KelseyPanMD, & @MirLimMD presenting their research today on #crcsm day at @ASCO #GI25 ! Future is looking bright with their brilliant minds to #endcancer !
Mir Lim retweeted
👉👉👉Superb clinic & research teams working together in #TeamPemm clinic #leusm #BPDCN #MPNSM this month ! @MDAndersonNews #endcancer | L➡️R @doctorpemm Michelle Golez RNTerri Saenz RN Rhona Pinsoy RN
Dr .@MirLimMD Dr Kekejian, Rodney Haltom PA 🙌
Mir Lim retweeted
Join us in congratulating our resident physicians who are preparing to pursue advanced training through fellowship programs in their chosen specialty! @UTSWIMchief @thomasjwang1 @DinoKazi @UTSWNews
📷
Mir Lim retweeted
Thrilled to welcome the newest class of hematology/medical oncology fellows to @MDAndersonNews!
Excited to work with all of you during training! #EndCancer
Mir Lim retweeted
IPI+NIVO after prior PD1/L1 in HCC?
➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4)
➡️ORR 22% (7/32)
➡️All responders to late line IPI+NIVO had NONRESPONSE to prior PD1/L1
ncbi.nlm.nih.gov/pmc/article…
Mir Lim retweeted
Very happy to be partnering with UT Southwestern Medical Center to provide our #NutritionEducation course to medical students in the ambulatory clerkship program! Welcome to those students who begin their nutrition course today! 🩺🍓
#MedEd #FoodAsMedicine #FoodIsMedicine #MedEd
